{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T12:26:33Z","timestamp":1792499193410,"version":"4.5.0"},"reference-count":49,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","joms.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Oral and Maxillofacial Surgery"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.joms.2024.06.162","type":"journal-article","created":{"date-parts":[[2024,6,15]],"date-time":"2024-06-15T00:17:09Z","timestamp":1718410629000},"page":"1285-1294","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["The Risk of Medication-Related Osteonecrosis of the Jaw in Children: Guidance for Antiresorptive Use in Pediatric Patients"],"prefix":"10.1016","volume":"82","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-3336-0540","authenticated-orcid":false,"given":"Sasha","family":"Lasky","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tayla","family":"Moshal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pasha","family":"Shakoori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-7843-583X","authenticated-orcid":false,"given":"Idean","family":"Roohani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marah","family":"Jolibois","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1251-6552","authenticated-orcid":false,"given":"Simon","family":"Youn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark M.","family":"Urata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0030-1420","authenticated-orcid":false,"given":"Jeffrey A.","family":"Hammoudeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.joms.2024.06.162_bib1","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.joms.2016.06.007","article-title":"Adjuvant antiangiogenic treatment for aggressive giant cell lesions of the jaw: A 20-year experience at massachusetts general hospital","volume":"75","author":"Schreuder","year":"2017","journal-title":"J Oral Maxillofac Surg"},{"key":"10.1016\/j.joms.2024.06.162_bib2","doi-asserted-by":"crossref","first-page":"988","DOI":"10.2174\/1389557519666190424163044","article-title":"Bisphosphonates and cancer: A Relationship beyond the antiresorptive effects","volume":"19","author":"Teixeira","year":"2019","journal-title":"Mini Rev Med Chem"},{"key":"10.1016\/j.joms.2024.06.162_bib3","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1016\/S1470-2045(13)70277-8","article-title":"Safety and efficacy of denosumab for adults and skeletally mature adolescents with giant cell tumour of bone: Interim analysis of an open-label, parallel-group, phase 2 study","volume":"14","author":"Chawla","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.joms.2024.06.162_bib4","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1016\/j.joms.2007.03.030","article-title":"Adjuvant antiangiogenic therapy for giant cell tumors of the jaws","volume":"65","author":"Kaban","year":"2007","journal-title":"J Oral Maxillofac Surg"},{"key":"10.1016\/j.joms.2024.06.162_bib5","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1016\/j.ejso.2018.03.020","article-title":"Denosumab treatment of inoperable or locally advanced giant cell tumor of bone - Multicenter analysis outside clinical trial","volume":"44","author":"Rutkowski","year":"2018","journal-title":"Eur J Surg Oncol"},{"key":"10.1016\/j.joms.2024.06.162_bib6","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1016\/S1470-2045(19)30663-1","article-title":"Denosumab in patients with giant-cell tumour of bone: A multicentre, open-label, phase 2 study","volume":"20","author":"Chawla","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.joms.2024.06.162_bib7","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1186\/1471-2407-10-462","article-title":"Bisphosphonate treatment of aggressive primary, recurrent and metastatic Giant Cell Tumour of Bone","volume":"10","author":"Balke","year":"2010","journal-title":"BMC Cancer"},{"key":"10.1016\/j.joms.2024.06.162_bib8","first-page":"181","article-title":"Bisphosphonate-Related Osteonecrosis of the Jaw (BRONJ) therapy. A critical review","volume":"59","author":"Vescovi","year":"2010","journal-title":"Minerva Stomatol"},{"key":"10.1016\/j.joms.2024.06.162_bib9","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1016\/j.joms.2022.02.008","article-title":"American association of oral and maxillofacial surgeons\u2019 position paper on medication-related osteonecrosis of the jaws-2022 update","volume":"80","author":"Ruggiero","year":"2022","journal-title":"J Oral Maxillofac Surg"},{"key":"10.1016\/j.joms.2024.06.162_bib10","doi-asserted-by":"crossref","first-page":"8580","DOI":"10.1200\/JCO.2005.02.8670","article-title":"Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: Incidence and risk factors","volume":"23","author":"Bamias","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.joms.2024.06.162_bib11","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.job.2019.03.005","article-title":"Medication-related osteonecrosis of the jaw: A literature review","volume":"61","author":"Kuroshima","year":"2019","journal-title":"J Oral Biosci"},{"key":"10.1016\/j.joms.2024.06.162_bib12","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/S0140-6736(10)62344-6","article-title":"Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: A randomised, double-blind study","volume":"377","author":"Fizazi","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.joms.2024.06.162_bib13","first-page":"e326","article-title":"Medication-related osteonecrosis of the jaws (MRONJ) in cancer patients treated with denosumab VS. zoledronic acid: A systematic review and meta-analysis","volume":"25","author":"Limones","year":"2020","journal-title":"Med Oral Patol Oral Cir Bucal"},{"key":"10.1016\/j.joms.2024.06.162_bib14","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/S1470-2045(18)30072-X","article-title":"Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: An international, double-blind, double-dummy, randomised, controlled, phase 3 study","volume":"19","author":"Raje","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.joms.2024.06.162_bib15","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1634\/theoncologist.2012-0261","article-title":"Adjuvant therapy with zoledronic acid in patients with breast cancer: A systematic review and meta-analysis","volume":"18","author":"Valachis","year":"2013","journal-title":"Oncol"},{"key":"10.1016\/j.joms.2024.06.162_bib16","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.ctrv.2012.07.002","article-title":"Denosumab in patients with cancer and skeletal metastases: A systematic review and meta-analysis","volume":"39","author":"Peddi","year":"2013","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.joms.2024.06.162_bib17","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1016\/j.joms.2022.06.026","article-title":"Medication-related osteonecrosis of the jaws in the pediatric population","volume":"80","author":"Neal","year":"2022","journal-title":"J Oral Maxillofac Surg"},{"key":"10.1016\/j.joms.2024.06.162_bib18","doi-asserted-by":"crossref","DOI":"10.5037\/jomr.2013.4401","article-title":"Systematic review on the incidence of bisphosphonate related osteonecrosis of the jaw in children diagnosed with osteogenesis imperfecta","volume":"4","author":"Hennedige","year":"2013","journal-title":"J Oral Maxillofac Res"},{"key":"10.1016\/j.joms.2024.06.162_bib19","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1111\/jop.12516","article-title":"Use of new targeted cancer therapies in children: Effects on dental development and risk of jaw osteonecrosis: A review","volume":"46","author":"Hernandez","year":"2017","journal-title":"J Oral Pathol Med"},{"key":"10.1016\/j.joms.2024.06.162_bib20","doi-asserted-by":"crossref","DOI":"10.3390\/dj9010007","article-title":"Role of innate inflammation in the regulation of tissue remodeling during tooth eruption","volume":"9","author":"Makino","year":"2021","journal-title":"Dent J"},{"key":"10.1016\/j.joms.2024.06.162_bib21","article-title":"Current knowledge on the healing of the extraction socket: A narrative review","volume":"10","author":"Udeabor","year":"2023","journal-title":"Bioengineering (Basel)"},{"key":"10.1016\/j.joms.2024.06.162_bib22","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/S1470-2045(19)30687-4","article-title":"Adjuvant denosumab in early breast cancer (D-CARE): An international, multicentre, randomised, controlled, phase 3 trial","volume":"21","author":"Coleman","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.joms.2024.06.162_bib23","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.jpeds.2008.05.003","article-title":"Tooth extraction socket healing in pediatric patients treated with intravenous pamidronate","volume":"153","author":"Chahine","year":"2008","journal-title":"J Pediatr"},{"key":"10.1016\/j.joms.2024.06.162_bib24","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/s11914-017-0380-1","article-title":"Denosumab: An emerging therapy in pediatric bone disorders","volume":"15","author":"Boyce","year":"2017","journal-title":"Curr Osteoporos Rep"},{"key":"10.1016\/j.joms.2024.06.162_bib25","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.ijom.2019.08.004","article-title":"Can children be affected by bisphosphonate-related osteonecrosis of the jaw? A systematic review","volume":"49","author":"Duarte","year":"2020","journal-title":"Int J Oral Maxillofac Surg"},{"issue":"Suppl 2","key":"10.1016\/j.joms.2024.06.162_bib26","doi-asserted-by":"crossref","first-page":"S66","DOI":"10.1007\/PL00004164","article-title":"Bisphosphonates: Pharmacology, mechanisms of action and clinical uses","volume":"9","author":"Russell","year":"1999","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.joms.2024.06.162_bib27","doi-asserted-by":"crossref","first-page":"20743","DOI":"10.18632\/aging.104006","article-title":"Determination of the molecular mechanism by which macrophages and \u03b3\u03b4-T cells contribute to ZOL-induced ONJ","volume":"12","author":"Qu","year":"2020","journal-title":"Aging"},{"key":"10.1016\/j.joms.2024.06.162_bib28","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1007\/s00774-020-01174-2","article-title":"Tooth extraction in mice administered zoledronate increases inflammatory cytokine levels and promotes osteonecrosis of the jaw","volume":"39","author":"Soma","year":"2021","journal-title":"J Bone Miner Metab"},{"key":"10.1016\/j.joms.2024.06.162_bib29","first-page":"123","article-title":"Bone health in childhood: Usefulness of biochemical biomarkers","volume":"19","author":"Eapen","year":"2008","journal-title":"EJIFCC"},{"key":"10.1016\/j.joms.2024.06.162_bib30","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1097\/BPO.0000000000000552","article-title":"Unusual femur stress fractures in children with osteogenesis imperfecta and intramedullary rods on long-term intravenous pamidronate therapy","volume":"36","author":"Hegazy","year":"2016","journal-title":"J Pediatr Orthop"},{"key":"10.1016\/j.joms.2024.06.162_bib31","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1002\/jbmr.2805","article-title":"Recurrent proximal femur fractures in a teenager with osteogenesis imperfecta on continuous bisphosphonate therapy: Are we overtreating?","volume":"31","author":"Vasanwala","year":"2016","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.joms.2024.06.162_bib32","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1093\/annonc\/mdr435","article-title":"Incidence, risk factors, and outcomes of osteonecrosis of the jaw: Integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases","volume":"23","author":"Saad","year":"2012","journal-title":"Ann Oncol"},{"key":"10.1016\/j.joms.2024.06.162_bib33","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.oooo.2018.08.015","article-title":"Prevalence, initiating factor, and treatment outcome of medication-related osteonecrosis of the jaw-a 4-year prospective study","volume":"126","author":"Hallmer","year":"2018","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol"},{"key":"10.1016\/j.joms.2024.06.162_bib34","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.bone.2019.03.031","article-title":"Vasculature submucosal changes at early stages of osteonecrosis of the jaw (ONJ)","volume":"123","author":"Gkouveris","year":"2019","journal-title":"Bone"},{"key":"10.1016\/j.joms.2024.06.162_bib35","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1002\/jbmr.3285","article-title":"SIRT1\/HERC4 Locus associated with bisphosphonate-induced osteonecrosis of the jaw: An exome-wide association analysis","volume":"33","author":"Yang","year":"2018","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.joms.2024.06.162_bib36","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.3892\/or.2011.1152","article-title":"Zoledronic acid, a third-generation bisphosphonate, inhibits cellular growth and induces apoptosis in oral carcinoma cell lines","volume":"25","author":"Tamura","year":"2011","journal-title":"Oncol Rep"},{"key":"10.1016\/j.joms.2024.06.162_bib37","doi-asserted-by":"crossref","first-page":"944","DOI":"10.3109\/07357907.2010.512598","article-title":"Anticancer properties of zoledronic acid","volume":"28","author":"Green","year":"2010","journal-title":"Cancer Invest"},{"key":"10.1016\/j.joms.2024.06.162_bib38","doi-asserted-by":"crossref","first-page":"272","DOI":"10.4103\/2278-330X.119895","article-title":"Denosumab: A comprehensive review","volume":"2","author":"Narayanan","year":"2013","journal-title":"South Asian J Cancer"},{"key":"10.1016\/j.joms.2024.06.162_bib39","article-title":"Hypercalcemia following discontinuation of denosumab therapy: A systematic review","volume":"15","author":"Horiuchi","year":"2021","journal-title":"Bone Rep"},{"key":"10.1016\/j.joms.2024.06.162_bib40","article-title":"Denosumab-induced rebound hypercalcemia treated with bisphosphonates in a pediatric patient","volume":"1","author":"Gandolfi","year":"2023","journal-title":"JCEM Case Rep"},{"key":"10.1016\/j.joms.2024.06.162_bib41","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1007\/s002239900353","article-title":"An in vitro and in vivo study of cytokines in the acute-phase response associated with bisphosphonates","volume":"61","author":"Thi\u00e9baud","year":"1997","journal-title":"Calcif Tissue Int"},{"key":"10.1016\/j.joms.2024.06.162_bib42","doi-asserted-by":"crossref","DOI":"10.1016\/j.bone.2020.115523","article-title":"Bisphosphonates in common pediatric and adult bone sarcomas","volume":"139","author":"Heymann","year":"2020","journal-title":"Bone"},{"key":"10.1016\/j.joms.2024.06.162_bib43","doi-asserted-by":"crossref","DOI":"10.1002\/jbm4.10210","article-title":"Use of denosumab in children with osteoclast bone Dysplasias: Report of three cases","volume":"3","author":"Upfill-Brown","year":"2019","journal-title":"JBMR Plus"},{"key":"10.1016\/j.joms.2024.06.162_bib44","doi-asserted-by":"crossref","first-page":"5057","DOI":"10.1158\/1078-0432.CCR-23-1966","article-title":"Zoledronic acid add-on therapy for standard-risk Ewing sarcoma patients in the Ewing 2008R1 trial","volume":"29","author":"Koch","year":"2023","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.joms.2024.06.162_bib45","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.pharmthera.2015.11.008","article-title":"Bisphosphonates for cancer treatment: Mechanisms of action and lessons from clinical trials","volume":"158","author":"Van Acker","year":"2016","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.joms.2024.06.162_bib46","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.taap.2012.01.024","article-title":"Reduction of metastasis, cell invasion, and adhesion in mouse osteosarcoma by YM529\/ONO-5920-induced blockade of the Ras\/MEK\/ERK and Ras\/PI3K\/Akt pathway","volume":"259","author":"Tsubaki","year":"2012","journal-title":"Toxicol Appl Pharmacol"},{"key":"10.1016\/j.joms.2024.06.162_bib47","first-page":"24","article-title":"Safety and efficacy of denosumab in children with osteogenesis imperfect--a first prospective trial","volume":"16","author":"Hoyer-Kuhn","year":"2016","journal-title":"J Musculoskelet Neuronal Interact"},{"key":"10.1016\/j.joms.2024.06.162_bib48","first-page":"76","article-title":"Hypercalcemia and hypercalciuria during denosumab treatment in children with osteogenesis imperfecta type VI","volume":"18","author":"Trejo","year":"2018","journal-title":"J Musculoskelet Neuronal Interact"},{"key":"10.1016\/j.joms.2024.06.162_bib49","first-page":"183","article-title":"First use of the RANKL antibody denosumab in osteogenesis imperfecta type VI","volume":"12","author":"Semler","year":"2012","journal-title":"J Musculoskelet Neuronal Interact"}],"container-title":["Journal of Oral and Maxillofacial Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0278239124005408?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0278239124005408?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,21]],"date-time":"2024-11-21T22:35:15Z","timestamp":1732228515000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0278239124005408"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":49,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["S0278239124005408"],"URL":"https:\/\/doi.org\/10.1016\/j.joms.2024.06.162","relation":{},"ISSN":["0278-2391"],"issn-type":[{"value":"0278-2391","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Risk of Medication-Related Osteonecrosis of the Jaw in Children: Guidance for Antiresorptive Use in Pediatric Patients","name":"articletitle","label":"Article Title"},{"value":"Journal of Oral and Maxillofacial Surgery","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.joms.2024.06.162","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 American Association of Oral and Maxillofacial Surgeons","name":"copyright","label":"Copyright"}]}}